Page last updated: 2024-08-17

adenosine monophosphate and Bleeding

adenosine monophosphate has been researched along with Bleeding in 51 studies

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (5.88)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (7.84)	29.6817
2010's	38 (74.51)	24.3611
2020's	6 (11.76)	2.80

Authors

Authors	Studies
Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Peterson, BE; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD	1
Ji, CS; Roberts, RJ; Solomon, EJ; Toyoda, AY; Yun, AN	1
Berti, S; Bolognese, L; Calabrò, P; Capranzano, P; Cernetti, C; Chirillo, F; Cirillo, P; Contarini, M; De Luca, L; Di Mario, C; Ferlini, M; Lanzilotti, V; Maffeo, D; Mauro, C; Menichelli, M; Menozzi, A; Muraglia, S; Musumeci, G; Nicolini, E; Pepe, M; Rolfo, C; Rossini, R; Scherillo, M; Talanas, G; Tarantini, G; Tomai, F; Trani, C; Versaci, F	1
Berry, TP; Haines, MM; Hayes, CH; Kozinn, JB; Mohamed, AM; Pluenneke, JC; Thomas, EL; Welge, JA; Zhurav, L	1
Ben-Dor, I; Bernardo, NL; Case, BC; Chezar-Azerrad, C; Forrestal, BJ; Garcia-Garcia, HM; Hashim, H; Medranda, GA; Satler, LF; Shea, C; Waksman, R; Yerasi, C; Zhang, C	1
Nei, SD; Seelhammer, TG; Skiba, J; Wittwer, ED	1
Alexopoulos, D; Lekakis, J; Pappas, C; Sfantou, D	1
Droppa, M; Geisler, T	1
Angiolillo, DJ; Bhatt, DL; Deliargyris, EN; Gibson, CM; Groves, EM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD	1
Amin, AP; Bhatt, DL; Fan, W; Généreux, P; Gibson, CM; Harrington, RA; Kirtane, AJ; Pinto, DS; Stone, GW; Tamez, H; White, HD; Yeh, RW	1
DeVore, AD; Milano, CA; Patel, CB; Washam, JB; Welsby, IJ; Yerokun, B	1
Calnan, MW; Crawford, AN	1
Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA	1
Erlinge, D; Grimfjärd, P; James, S; Lagerqvist, B; Varenhorst, C	1
Abtan, J; Bhatt, DL; Deliargyris, EN; Ducrocq, G; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD	1
Angiolillo, DJ; Bhatt, DL; Bramucci, E; Gallup, D; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; McLaurin, BT; Prats, J; Price, MJ; Radke, PW; Skerjanec, S; Spriggs, D; Steg, PG; Stone, GW; Tauth, J; Todd, M; Tousek, F; White, HD; Widimský, P	1
Mitka, M	1
Bhatt, DL; Day, JR; French, WJ; Gibson, CM; Gogia, HS; Gruberg, L; Hamm, CW; Harrington, RA; Iwaoka, RS; Leonardi, S; Liu, T; Mahaffey, KW; Skerjanec, S; Steg, PG; Stone, GW; Stuckey, TD; White, HD	1
Chatterjee, S; Mushiyev, S; Nairooz, R; Pekler, G; Sardar, P; Visco, F	1
Aradi, D; Kim, MH; Serebruany, VL; Sibbing, D	1
Limbruno, U; Musumeci, G	1
Jover, E; Tello-Montoliu, A; Valdés, M	1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ	1
Sabouret, P; Taiel-Sartral, M	1
Bonadei, I; D'Aloia, A; Metra, M; Raddino, R; Sciatti, E; Vizzardi, E	1
Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M	1
Guasti, L; Riva, N; Squizzato, A; Tamborini Permunian, E	1
Angiolillo, DJ; Bhatt, DL; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD	1
Keating, GM	1
Bye, AP; Fry, MJ; Gibbins, JM; Stainer, AR; Unsworth, AJ; Vaiyapuri, S	1
Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD	1
Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; O'Donoghue, ML; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD	1
Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Jatene, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD	1
Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD	1
Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD	1
Bhatt, DL; Fuster, V; Gersh, BJ; Lennon, RJ; Narula, J; Rihal, CS; Singh, M; Stone, GW	1
Bhatt, DL; Deliargyris, EN; Elkin, S; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD	1
Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD	1
Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD	1
Arneja, J; Bhatt, DL; Chew, DP; Cura, F; Gibson, CM; Goodman, SG; Harrington, RA; Jafar, MZ; Kleiman, NS; Lincoff, AM; Mahaffey, KW; Manoukian, SV; Manukov, I; McNulty, S; Montalescot, G; Pollack, CV; Skerjanec, S; Stone, GW; Tousek, F; White, HD; Widimsky, P	1
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J	1
Lee, KL	1
Frey, N; Ivandic, B	1
Cattaneo, M	1
Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J	1
Costa, MM; Da Silva, AS; França, RT; Jaques, JA; Leal, DB; Lopes, ST; Mazzanti, CM; Monteiro, SG; Paim, CB; Paim, FC; Pimentel, VC; Schetinger, MR; Souza, VC	1
Dawood, BB; Watson, SP; Wilde, J	1
Boiarinov, GA; Khvorov, NV; Shvets, NA; Snopova, LB	1
Kozhura, VL	1
Heidenreich, O; Osswald, H; Schmitz, HJ	1

Reviews

16 review(s) available for adenosine monophosphate and Bleeding

Article	Year
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives. Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:1 Topics: Adenosine Monophosphate; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine	2018
What is the Role of Cangrelor in Patients Undergoing PCI? Current vascular pharmacology, 2018, Volume: 16, Issue:5 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Coronary Artery Disease; Coronary Thrombosis; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Treatment Outcome	2018
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet (London, England), 2013, Dec-14, Volume: 382, Issue:9909 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Cause of Death; Coronary Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Treatment Outcome	2013
Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials. Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:1 Topics: Adenosine Monophosphate; Female; Hemorrhage; Humans; Male; Models, Biological; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; PubMed; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thrombosis	2014
Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials. International journal of cardiology, 2013, Nov-05, Volume: 169, Issue:3 Topics: Adenosine Monophosphate; Hemorrhage; Humans; Infusions, Intravenous; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors	2013
[New antiplatelet drugs in coronary artery disease]. Medicina clinica, 2014, Dec-09, Volume: 143, Issue:11 Topics: Adenosine; Adenosine Monophosphate; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Double-Blind Method; Dyspnea; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Treatment Outcome	2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2014
New antiplatelet agents in the treatment of acute coronary syndromes. Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel. Recent patents on cardiovascular drug discovery, 2014, Volume: 9, Issue:1 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Hemorrhage; Humans; Patents as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides	2014
Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data. Expert opinion on drug metabolism & toxicology, 2015, Volume: 11, Issue:4 Topics: Adenosine Monophosphate; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis	2015
Cangrelor: A Review in Percutaneous Coronary Intervention. Drugs, 2015, Volume: 75, Issue:12 Topics: Adenosine Monophosphate; Administration, Intravenous; Blood Platelets; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Treatment Outcome	2015
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clinic proceedings, 2016, Volume: 91, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Antithrombins; Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Genotype; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor	2016
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2009
[New approaches and indications for the analysis of platelet function in cardiology]. Hamostaseologie, 2011, May-02, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2011
[Myocardial infarction: Role of new antiplatelet agents]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors	2011

Trials

13 trial(s) available for adenosine monophosphate and Bleeding

Article	Year
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circulation. Cardiovascular interventions, 2022, Volume: 15, Issue:3 Topics: Adenosine Monophosphate; Hemorrhage; Humans; Myocardial Infarction; Obesity; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Treatment Outcome	2022
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2018, 11-01, Volume: 92, Issue:5 Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Hemorrhage; Hospital Costs; Hospital Mortality; Humans; Length of Stay; Male; Middle Aged; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Time Factors; Treatment Outcome; United States	2018
Effect of platelet inhibition with cangrelor during PCI on ischemic events. The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14 Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine	2013
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3 Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome	2015
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:3 Topics: Adenosine Monophosphate; Drug Overdose; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention	2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. European heart journal, 2016, Apr-07, Volume: 37, Issue:14 Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femoral Artery; Graft Occlusion, Vascular; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Radial Artery; Stents; Ticlopidine; Treatment Outcome	2016
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. Circulation, 2016, Jan-19, Volume: 133, Issue:3 Topics: Adenosine Monophosphate; Aged; Aged, 80 and over; Disease Management; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sex Characteristics; Treatment Outcome	2016
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circulation. Cardiovascular interventions, 2016, Volume: 9, Issue:6 Topics: Adenosine Monophosphate; Aged; Brazil; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Europe; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; New Zealand; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Thailand; Ticlopidine; Time Factors; Treatment Outcome; United States	2016
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. JACC. Cardiovascular interventions, 2016, 09-26, Volume: 9, Issue:18 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome	2016
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA cardiology, 2017, 02-01, Volume: 2, Issue:2 Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Treatment Outcome; United States	2017
Platelet inhibition with cangrelor in patients undergoing PCI. The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Treatment Failure	2009
Intravenous platelet blockade with cangrelor during PCI. The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Stents; Treatment Outcome	2009
Reference curves for aggregation and ATP secretion to aid diagnose of platelet-based bleeding disorders: effect of inhibition of ADP and thromboxane A(2) pathways. Platelets, 2007, Volume: 18, Issue:5 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Blood Platelets; Cyclooxygenase Inhibitors; Diagnosis, Differential; Female; Hemorrhage; Humans; Indomethacin; Male; Platelet Aggregation; Platelet Function Tests; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Reference Standards; Secretory Vesicles; Thromboxane A2	2007

Other Studies

22 other study(ies) available for adenosine monophosphate and Bleeding

Article	Year
Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide. Journal of cardiovascular pharmacology, 2022, 03-01, Volume: 79, Issue:3 Topics: Adenosine Monophosphate; Eptifibatide; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Treatment Outcome	2022
Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. Clinical cardiology, 2022, Volume: 45, Issue:9 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Adult; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome	2022
Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support. Journal of cardiothoracic and vascular anesthesia, 2023, Volume: 37, Issue:12 Topics: Adenosine Monophosphate; Adolescent; Cohort Studies; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Thrombosis; Treatment Outcome	2023
Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. American heart journal, 2021, Volume: 238 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Female; Gastrointestinal Hemorrhage; Hematocrit; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction	2021
Maintenance of Drug-Eluting Stent Patency Through Use of a Cangrelor Infusion in the Clinical Setting of Massive Pulmonary Hemorrhage and Venoarterial Extracorporeal Membrane Oxygenation. Journal of cardiothoracic and vascular anesthesia, 2017, Volume: 31, Issue:6 Topics: Adenosine Monophosphate; Combined Modality Therapy; Drug-Eluting Stents; Electrocardiography; Extracorporeal Membrane Oxygenation; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Pulmonary Edema	2017
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation. Cardiovascular interventions, 2018, Volume: 11, Issue:4 Topics: Adenosine Monophosphate; Aged; Clopidogrel; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thrombocytopenia; Time Factors; Treatment Outcome	2018
Cangrelor use prior to left ventricular assist device surgery: a case series. Journal of thrombosis and thrombolysis, 2018, Volume: 46, Issue:2 Topics: Adenosine Monophosphate; Aged; Cardiovascular Surgical Procedures; Female; Heart Ventricles; Heart-Assist Devices; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Shock, Cardiogenic	2018
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy. Journal of pharmacy practice, 2020, Volume: 33, Issue:2 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor	2020
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention. Cardiovascular revascularization medicine : including molecular interventions, 2019, Volume: 20, Issue:9 Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome	2019
intravenous cangrelor (Kengrexal°) and coronary angioplasty: No advantage over first-line clopidogrel. Prescrire international, 2016, Volume: 25, Issue:175 Topics: Adenosine Monophosphate; Administration, Intravenous; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome	2016
Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). European heart journal. Cardiovascular pharmacotherapy, 2019, 07-01, Volume: 5, Issue:3 Topics: Adenosine Monophosphate; Aged; Coronary Thrombosis; Drug Utilization; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Sweden; Time Factors; Treatment Outcome	2019
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y Circulation. Cardiovascular interventions, 2019, Volume: 12, Issue:3 Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Stents; Time Factors; Treatment Outcome	2019
Study ignites debate on new anticoagulant. JAMA, 2013, May-01, Volume: 309, Issue:17 Topics: Adenosine Monophosphate; Drug Approval; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome	2013
[The CHAMPION PHOENIX study]. Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:10 Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Double-Blind Method; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Ticlopidine	2013
Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:11 Topics: Adenine; Adenosine Monophosphate; Agammaglobulinaemia Tyrosine Kinase; Blood Platelets; Calcium Signaling; Collagen; Dose-Response Relationship, Drug; Fibrinogen; Hemorrhage; Hemostasis; Humans; Piperidines; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyrimidines; Risk Factors; Time Factors	2015
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. Journal of the American College of Cardiology, 2016, Feb-09, Volume: 67, Issue:5 Topics: Adenosine Monophosphate; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Research Design	2016
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:1 Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome	2017
Testing a new approach for rapid and reversible platelet inhibition during percutaneous coronary intervention among patients with acute coronary syndrome. Hospital practice (1995), 2010, Volume: 38, Issue:1 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Stents; Treatment Outcome	2010
Activities of ectonucleotidases and adenosine deaminase in platelets of dogs experimentally infected with Rangelia vitalii. Experimental parasitology, 2012, Volume: 131, Issue:2 Topics: Adenosine; Adenosine Deaminase; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Babesia; Babesiosis; Blood Coagulation Disorders; Blood Platelets; Brazil; Deamination; Dog Diseases; Dogs; Female; Hemorrhage; Hydrolysis; Nucleotidases; Platelet Count	2012
[Effect of sodium oxybutyrate on macroergic phosphates, function and ultrastructure of the myocardium in blood loss]. Biulleten' eksperimental'noi biologii i meditsiny, 1984, Volume: 97, Issue:3 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Creatine; Dogs; Energy Metabolism; Heart; Hemodynamics; Hemorrhage; Hydroxybutyrates; Hypotension; Myocardium; Phosphocreatine; Sodium Oxybate	1984
[Energy potential of the cerebral cortex in the pre-agonal and post-resuscitation period after acute blood loss]. Biulleten' eksperimental'noi biologii i meditsiny, 1977, Volume: 84, Issue:11 Topics: Acute Disease; Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Brain Chemistry; Dogs; Female; Hemorrhage; Male; Resuscitation	1977
Adenosine response of the rat kidney after saline loading, sodium restriction and hemorrhagia. Pflugers Archiv : European journal of physiology, 1975, Jun-26, Volume: 357, Issue:3-4 Topics: Adenosine; Adenosine Monophosphate; Angiotensin II; Animals; Blood Flow Velocity; Blood Pressure; Glomerular Filtration Rate; Hemorrhage; Kidney; Male; Rats; Renin; Sodium	1975